More Senate questions for Henney
This article was originally published in The Gray Sheet
Executive Summary
FDA Commissioner-nominee Jane Henney, MD, is asked to provide her "general understanding" of FDA's policy regarding advertising and promoting laser-assisted in situ keratomileusis (LASIK) procedures with unapproved "black box" lasers and approved lasers. The question is one of 24 submitted to the nominee on Oct. 1 by Sen. Orrin Hatch (R-Utah.), who also asks Henney whether it would be in the interest of "public health if an [over-the-counter] home drug analysis test kit came on the market." In addition to the questions, Hatch requests a meeting with Henney to discuss her responses, the need for which could postpone the Senate's consideration of the nomination past the target adjournment date of Oct. 9
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.